Boehringer Must Show How IP 'Thicket' Blocked Humira Rival
Boehringer Ingelheim must hand over its launch plans for a biosimilar version of AbbVie Inc.'s hugely popular immunosuppressant Humira, a Delaware magistrate judge has ruled in a patent infringement case, finding...To view the full article, register now.
Already a subscriber? Click here to view full article